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Summary
Background: Although drug-eluting stents (DES) have been shown to dramatically
reduce restenosis and improve the rate of event-free survival in large randomized
trials, the beneﬁt of DES appears to be limited to restenosis. In large arteries, it
is not clear which type of stent is more superior in angiographic and clinical out-
comes between DES and bare-metal stents (BMS). We compared the angiographic
and clinical outcomes of DES versus BMS in large arteries (≥3.5mm).
Method: Two hundred and forty patients from March 2002 to March 2007 received
stents; 196 patients were treated with DES (44.9% sirolimus-eluting stents;
43.9% paclitaxel-eluting stents; 11.2% zotarolimus-eluting stents) and 44 with
cobalt—chromium BMS for single de novo lesions in a large vessel. All subjects
received aspirin, clopidogrel, and/or cilostazol as the standard antiplatelet regimen.
The angiographic and clinical outcomes were evaluated at 6 months.
Results: For the baseline characteristics, there were no signiﬁcant differences
between the DES and BMS groups. In addition, for the initially implanted
stent there was no difference in the length, stent diameter, and lesion site
between the two groups. After 6 months, the follow-up angiogram showed
that in-stent diameter restenosis and late loss was more common with BMS
than DES (39± 21% vs. 19± 17%, p = 0.007; 1.44± 0.83mm vs. 0.62± 0.58mm,
p = 0.009, respectively). However, the target-lesion revascularization/target-vessel
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showed equally favorable 6-month clinical outcomes, although the 6-month angio-
more favorable in the DES group than in the BMS group.
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Deﬁnitions and end pointsgraphic results appeared
© 2009 Published by Else
ntroduction
ince sirolimus-eluting (Cypher; Cordis Corpora-
ion, Miami, FL, USA) and paclitaxel-eluting (Taxus;
oston Scientiﬁc Corporation, San Diego, CA, USA)
tents were introduced and approved by the US
ood and Drug Administration (FDA) in 2003—2004,
are-metal stents (BMS) have been rapidly replaced
y drug-eluting stents (DES). Many large random-
zed trials have demonstrated that DES markedly
educe restenosis and improve the rate of event-
ree survival [1—3]. However, the frequency of
yocardial infarction and survival rates has not
ecreased with DES [4,5]. Furthermore, the advan-
ages of DES over BMS have not been conﬁrmed for
arger coronary arteries; larger coronary arteries
an adapt to intimal hyperplasia, and the need for
epeat target-lesion revascularization is decreased
6—8]. Nevertheless, the utilization of DES has been
idespread, regardless of the vessel size, and con-
erns with regard to their long-term safety and cost
ave been raised [9].
We investigated three types of DES and a type
f cobalt—chromium BMS (Driver; Medtronic, Min-
eapolis, MN, USA) with regard to the 6-month
linical and angiographic outcomes for single large
≥3.5mm) vessel interventions.
ethods
tudy group
rom March 2002 to March 2007, a database
f patients was collected at the Cardiovascular
enter of Guro Hospital (Seoul, Korea). Patients
ho were treated for large (≥3.5mm) single de
ovo lesions located in a native coronary ves-
el resulting in stenosis of 70—99% of the luminal
iameter were enrolled in the study. Subjects
ad a history of stable or unstable angina and
ll received percutaneous coronary intervention
PCI). The types of DES were: sirolimus-eluting
tent, paclitaxel-eluting stent and zotarolimus-
luting stent (Endeavor; Medtronic) and the type
f BMS was the cobalt—chromium stent (Driver;
W
m
w
eIreland Ltd on behalf of Japanese College of Cardiology.
edtronic). The major exclusion criteria were
cute ST segment elevation myocardial infarc-
ion or acute non-ST segment elevation myocardial
nfarction, cardiogenic shock, underlying structural
eart disease including hypertrophic cardiomy-
pathy, previous bypass graft surgery, a serum
reatinine level of more than 2.0mg/dl, age under
8 years, contraindication or allergy to antiplatelet
gents or contrast medium, life expectancy of less
han 1 year, and other serious medical conditions.
total of 240 patients were selected for the study;
96 patients were treated with DES and 44 patients
ere treated with a BMS.
rocedures
ll patients received oral aspirin (200mg for a load-
ng dose) and oral clopidogrel (300—600mg for a
oading dose) as the standard antiplatelet regimen.
uring the PCI, intravenous heparin boluses were
iven every hour to maintain an activated clotting
ime of 250—300 s. Additional use of intravenous
lycoprotein IIb/IIIa inhibitors was administered at
he physician’s discretion. After successfully wiring
o the target lesion, predilation was performed
sing 2.0—2.5mm diameter balloons and then the
tent was deployed until the nominal pressure (or
lus 2—4 atm.) was achieved. Additional balloon-
ng was performed if angiographically needed. After
nishing the procedure, all patients were treated
ith aspirin (100mg/day; indeﬁnitely) and clopi-
ogrel (75mg/day; 1 month for BMS, 6—12 months
or DES). Cilostazol (100mg/day; maximum for 2
eeks) was added in 4% of DES patients and in none
f BMS cases.
Pre- and postprocedural 12-lead electrocar-
iography was routinely performed and creatine
inase-MB levels assessed at 4 h, 12 h, and 24 h after
he PCI to detect postprocedural ischemic events.ronary artery 109
revascularization, and total major adverse cardiac events showed no signiﬁcant
differences between the groups (5.3% vs. 3.6%, p = 0.62; 5.3% vs. 4.6%, p = 0.86,
respectively).
Conclusion: The DES and cobalt—chromium BMS placed in large coronary arteriese deﬁned a large coronary artery as one that was
ore than 3.5mm in diameter. Procedural success
as deﬁned as residual stenosis <30% of the diam-
ter with a Thrombolysis In Myocardial Infarction
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(TIMI) ﬂow grade 3, and no evidence of compli-
cations (dissection, death, and Q-wave myocardial
infarction) of the PCI. Major adverse cardiac events
(MACEs) included death, a Q-wave/non-Q-wave
myocardial infarction, target-lesion revasculariza-
tion (TLR), and target-vessel revascularization
(TVR). Binary restenosis was deﬁned as a steno-
sis of more than 50% of the luminal diameter in
the target lesion. Late loss was deﬁned as the
difference in minimal luminal diameter between
the index procedure and the follow-up angiogra-
phy.
The clinical end point was a survival free of
death, myocardial infarction, TLR/TVR after 6
months in the BMS versus DES groups. The angio-
graphic outcomes compared with binary restenosis,
minimal luminal diameter (MLD), and late lumen
loss (LL).
Statistical analysis
All statistical analyses were done with Statisti-
cal Package for Social Science (SPSS) software
(version 13.0, SPSS Inc., Chicago, IL, USA). The
results are presented as means± standard devia-
tion. The Student’s t-test was used to compare
differences in the continuous variables, and the
Chi-square analysis was used to compare propor-
tions in the categorical variables. The cumulative
incidence of adverse events was estimated using
the Kaplan—Meier method. Differences between
the event-free survival curves for the two groups
were compared by log-rank test. A two-sided prob-
ability value of p < 0.05 was considered statistically
signiﬁcant.
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Table 1 Baseline characteristics.
DES group (N = 196)
Age, years 66.2± 9.7
Sex (male, %) 61.2
Stent type (%)
Cypher 44.9
Taxus 43.9
Endeavor 11.2
Underlying disease (%)
Hypertension 44.9
Diabetes 27.0
Smoking 32.1
Obesity (BMI > 25 kg/m2) 35.2
Hyperlipidemia 42.3
Family history for CVD 20.9
Previous CVD 11.2
DES, drug-eluting stent; BMS, bare-metal stent; CVD, cardiovasculaJ.O. Na et al.
esults
wo hundred and forty patients from March 2002
o March 2007 underwent stent procedures: 196
eceived DES (44.9% sirolimus-eluting stents; 43.9%
aclitaxel-eluting stents; 11.2% zotarolimus-eluting
tents) and 44 cobalt—chromium BMS for single de
ovo lesions in a large vessel. The baseline char-
cteristics are shown in Table 1. There were no
igniﬁcant differences in the baseline characteris-
ics between two groups.
The procedural characteristics are displayed in
able 2. Most of the culprit vessels were the left
nterior descending artery (41.7% in BMS group and
4.5% in DES group) and right coronary artery (44.4%
n BMS group and 31.4% in DES group). A left main
oronary artery lesion was found in 2.8% of the BMS
roup and 5.8% of the DES group. However, there
as no lesion site difference between the BMS and
ES groups. There was a tendency for the mean
tent length to be longer in the DES group than in
he BMS group; but this difference was not statis-
ically signiﬁcant (p = 0.38). In addition, there was
o difference in mean stent diameter (4.01mm in
MS and 3.96mm in DES group, p = 0.61).
A coronary angiogram was performed 6 months
fter the initial procedure in 38 out of 44 patients
n the BMS group and all 196 patients in the DES
roup. The 6-month clinical outcomes are shown
n Fig. 1. There were no signiﬁcant differences
etween the groups in the target-vessel and target-
esion revascularization rate (5.3% in BMS group and
.6% in DES group, p = 0.62). There were two cases
f MACEs that developed in the BMS group (5.3%)
nd nine cases in the DES group (4.6%); these dif-
erences were not statistically signiﬁcant (p = 0.86).
BMS group (N = 44) p-Value
69.0± 8.8 0.103
63.2 0.77
40.9 0.60
43.2 0.081
31.8 0.97
29.5 0.67
40.9 0.86
18.2 0.68
9.1 0.68
r disease; BMI, body mass index.
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Table 2 Procedural characteristics and 6-month outcomes.
BMS group DES group p-Value
Target vessel
Left main (%) 2.8 5.8 0.091
Left anterior descending (%) 41.7 54.5 0.62
Left circumﬂex (%) 11.1 9.3 0.57
Right coronary (%) 44.4 31.4 0.66
Type C lesion (%) 11.4 21.9 0.11
Minimal luminal diameter (mm)
Preprocedure 0.92± 0.53 0.80± 0.66 0.426
Postprocedure 4.07± 0.53 3.91± 0.40 0.092
Six months after procedure 2.65± 0.79 3.24± 0.92 0.004
Final balloon pressure (atm) 13.4± 3.2 14.4± 3.9 0.17
Stent length (mm) 19.7.6 24.6± 5.9 0.38
Stent diameter (mm) 4.01± 0.41 3.96± 0.47 0.61
TLR/TVR (6 months) (%) 2/38 (5.3) 7/196 (3.6) 0.62
MACE (6 months) (%) 2/38 (5.3) 9/196 (4.6)† 0.86
Diameter stenosis in-stent (%) 38.9± 20.8 18.5± 17.1 0.007
Late loss (mm) 1.44± 0.83 0.62± 0.58 0.009
Binary restenosis (%) 3/38 (7.8) 8/196 (4.1) 0.28
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major adverse cardiac events.
† In-hospital mortality 1; 6-month mortality 1; myocardial i
f the two cardiac deaths in the DES group, one
as due to sudden cardiac death while in the hos-
ital but autopsy was not done, and the other
ne was due to a myocardial infarction after dis-
harge (94 days after percutaneous intervention).
he 6-month angiographic outcomes showed that
n the BMS group, more late loss (1.44± 0.83mm
s. 0.62± 0.58mm, p = 0.009) developed and there
as a higher frequency of in-stent diameter steno-
is (38.9± 20.8% vs. 18.5± 17.1%, p = 0.007) than in
t
c
g
b
igure 1 Six-month event-free incidences of target-lesion/v
umulative 6-month incidence free from target-lesion and
omparable between the groups. TLR, target-lesion revascu
ajor adverse cardiac events.sion revascularization/target-vessel revascularization; MACE,
tion 1.
he DES group (Fig. 2A). However, there were no sig-
iﬁcant differences between the two groups for the
requency of binary restenosis (7.8% in BMS group
nd 4.1% in DES group, p = 0.28) (Fig. 2B). Also the
ame clinical and angiographic results were seen in
omparison between each type of DES group and
he BMS group. Although the late loss was signiﬁ-
antly higher in BMS group than each type of DES
roups, no signiﬁcant differences were seen in the
inary restenosis, TLR/TVR, and MACEs (Table 3).
essel revascularization (A) and composite MACE (B). The
target-vessel revascularization, and MACE curves were
larization; TVR, target-vessel revascularization; MACE,
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tFigure 2 Six-month angiographic outcomes. Although l
drug-eluting stents (DES) (A), binary restenosis did not su
Discussion
The results of this study showed that the 6-month
clinical outcomes, after PCI of large single de novo
coronary arteries, were excellent in both the BMS
and DES groups. For cases with a coronary artery
diameter of more than 3.5mm, the BMS had a favor-
able 6-month outcome with a low frequency of
cardiac events and was not inferior to the DES.
Our ﬁndings are also consistent with previous
studies [6,7]. Many prior studies have reported an
inverse relationship between the restenosis risk
and the vessel diameter after BMS implantation.
For the SIRolImUS-coated stent in the treatment
of patients with de novo coronary artery lesions
(SIRIUS) trial, they reported that a smaller vessel
size increased the risk of restenosis by multivariate
d
c
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Table 3 Clinical and angiographic outcomes comparison be
Cypher group
Late loss (mm) 0.59± 0.60
Binary restenosis (%) 3/88 (3.4)
TLR/TVR (6 months) (%) 2/88 (2.3)
MACE (6 months) (%) 4/88 (4.5)
Taxus group
Late loss (mm) 0.52± 0.48
Binary restenosis (%) 4/86 (4.7)
TLR/TVR (6 months) (%) 4/86 (4.7)
MACE (6 months) (%) 4/86 (4.7)
Endeavor group
Late loss (mm) 0.86± 0.59
Binary restenosis (%) 1/22 (4.5)
TLR/TVR (6 months) (%) 1/22 (4.5)
MACE (6 months) (%) 1/22 (4.5)
DES, drug-eluting stent; BMS, bare-metal stent; TLR/TVR, target-le
major adverse cardiac events.oss of bare-metal stents (BMS) was higher than that of
ntially differ between the groups (B).
nalysis [1]. In addition, according to the TAXUS-IV
ubgroup analysis, conﬁrmation of DES’s superior-
ty over BMS, in large coronary arteries (>3.0mm)
ailed to show a beneﬁt, but demonstrated supe-
iority of DES for smaller arteries (<3.0mm) [2].
n the TAXUS-V study, the 9-month adverse cardiac
vents in the 4.0-mm BMS (Express2, Boston Sci-
ntiﬁc Corporation) subgroup were not signiﬁcantly
igher than in the Taxus stent subgroup [5]. In addi-
ion, in the BeStent 2, a randomized study that
ompared the Cypher and thin strut BMS, although
he general restenosis rate of the DES was lower
han that of BMS by 67%, there was no signiﬁcant
ifference in angiographic and clinical restenosis in
ases with a vessel size greater than 2.8mm [10].
There are several reasons for similar outcomes
or the BMS and DES in large coronary arter-
tween each type of DES and BMS.
BMS group p-Value
1.44± 0.83 <0.01
3/38 (7.9) 0.29
2/38 (5.3) 0.40
2/38 (5.3) 0.88
BMS group p-Value
1.44± 0.83 <0.01
3/38 (7.9) 0.45
2/38 (5.3) 0.86
2/38 (5.3) 0.86
BMS group p-Value
1.44± 0.83 <0.01
3/38 (7.9) 0.62
2/38 (5.3) 0.92
2/38 (5.3) 0.92
sion revascularization/target-vessel revascularization; MACE,
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RMS vs DES in large single coronary artery
es. DES have been shown to be superior to
MS in the inhibition of neointimal hyperplasia
11,12]. As intravascular ultrasound studies have
uggested, small vessels cannot accommodate well
o neointimal hyperplasia after BMS implantation
13,14]. However, for large arteries, the superi-
rity of the DES is diminished because the same
egree of neointimal hyperplasia develops, and
he large arteries can more easily accommodate
ntimal hyperplasia than the small arteries [8].
his explains why although neointimal hyperplasia
evelops in large vessels, clinically or angiographi-
ally signiﬁcant restenosis is not likely to occur. For
xample, for the late loss of 1mm, binary restenosis
s under 50%, and there is adequate patency with-
ut the development of hemodynamic compromise
nd the need for further intervention. In addition,
t is important to recognize that the restenosis rate
epends on other clinical variables such as diabetes
nd lesion complexity as well as vessel size [15,16].
he patients in this study did not differ based on
heir clinical characteristics.
There have been numerous studies that have
hown the relative superiority of DES compared to
MS with regard to in-stent restenosis; however,
here has not been a study that has shown superior-
ty with regard to mortality. Furthermore, although
t is evident that DES treatment can reduce resteno-
is or clinically relevant events during the ﬁrst year
ompared to the BMS, rate catch-up phenomenon
f DESs was reported and repeat target revascu-
arization or stent thrombosis has been increasing
17,18]. We thought that the one case of in-hospital
udden cardiac death in the present study might
ave occurred due to acute thrombosis. So the long-
erm overall clinical beneﬁts are controversial. This
s especially true for late events related to very late
tent thrombosis and large native vessel stenting
an be more dangerous.
The concerns raised with regard to the DES
nclude the following. First, DES might be associ-
ted with delayed wound healing due to the effects
f sirolimus, paclitaxel or zotarolimus. Therefore,
ong-term dual antiplatelet agents are needed,
hich increase the danger of bleeding as well as
ost. Second, the risk for late restenosis and late
tent thrombosis after discontinuing antiplatelet
gents might be increased. Third, DES are much
ore expensive than BMS.
Considering the outcomes found in this study,
t is important to determine which patient group
as the same outcome, with both the DES and BMS.
he results of this study showed that the outcomes
or both the BMS and DES were the same for the
essels with a diameter over 3.5mm, after adjust-
ents for other factors. The proportion of diabetes113
n the BMS group was 42%, but it was only 27% in
he DES group — even though not statistically signif-
cant — we thought it a possible factor that affected
he outcomes. And to conclude, BMS can be recom-
ended as an option in cases with large vessel de
ovo single lesions after excluding high-risk condi-
ions such as chronic total occlusion, a diffuse long
esion, in-stent restenosis, and a bifurcation lesion.
The limitations of this study include the follow-
ng. The retrospective and non-randomized study
esign implies some degree of selection bias. In
ddition, the follow-up period was short because
f our policy for angiography follow-up, which is
months after the initial PCI. Furthermore, there
ere fewer subjects in the BMS group than in the
ES group. And there were three types of DES, but
nly one type of BMS; each of the DES types had a
imilar number of patients as the BMS group except
or the Endeavor type.
onclusion
he ﬁndings from the present study showed that
he DES and the cobalt—chromium BMS when placed
n a large single coronary artery, showed equally
avorable 6-month clinical outcomes, although the
-month angiographic results were more favorable
n the DES group than in the BMS group.
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